Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$421 Mln
P/E Ratio
--
P/B Ratio
3.77
Industry P/E
87.38
Debt to Equity
0.26
ROE
-0.12 %
ROCE
--
Div. Yield
0 %
Book Value
7.82
EPS
-1.02
CFO
$137.21 Mln
EBITDA
$117.22 Mln
Net Profit
$19.07 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
SurModics Inc (SRDX)
| -25.61 | -3.16 | -22.78 | 13.00 | -11.19 | -4.59 | 1.05 |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
SurModics Inc (SRDX)
| 8.86 | 6.54 | -29.14 | 10.64 | 5.04 | -12.34 | 68.30 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.93 | 10,562.04 | 12.43 | 12.69 | |
| 72.80 | 10,050.19 | 97.07 | 2.52 | |
| 163.74 | 8,847.72 | -- | -25.23 | |
| 299.78 | 11,550.00 | 278.74 | 3.65 |
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and... internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. Read more
CEO, President & Director
Mr. Gary R. Maharaj
CEO, President & Director
Mr. Gary R. Maharaj
Headquarters
Eden Prairie, MN
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of SurModics Inc (SRDX) stood at $ 177 Mln as on 31-Dec-24
The share price of SurModics Inc (SRDX) is $29.46 (NASDAQ) as of 25-Apr-2025 16:01 EDT. SurModics Inc (SRDX) has given a return of -11.19% in the last 3 years.
SurModics Inc (SRDX) has a market capitalisation of $ 421 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of SurModics Inc (SRDX) is 3.77 times as on 25-Apr-2025, a 5% premium to its peers’ median range of 3.59 times.
Since, TTM earnings of SurModics Inc (SRDX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the SurModics Inc (SRDX) and enter the required number of quantities and click on buy to purchase the shares of SurModics Inc (SRDX).
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
The CEO & director of Mr. Gary R. Maharaj. is SurModics Inc (SRDX), and CFO & Sr. VP is Mr. Gary R. Maharaj.
There is no promoter pledging in SurModics Inc (SRDX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| SurModics Inc (SRDX) | Ratios |
|---|---|
|
Return on equity(%)
|
-12.53
|
|
Operating margin(%)
|
-5.96
|
|
Net Margin(%)
|
-11.48
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of SurModics Inc (SRDX) was $0 Mln.
$0.06
(
